NasdaqCM:NKTRPharmaceuticals
A Look At Nektar Therapeutics (NKTR) Valuation After Prosight’s US$10 Million Purchase Ahead Of Phase 3 Trial
Institutional buying ahead of key Phase 3 trial
Prosight Management’s decision to buy about US$10 million of Nektar Therapeutics (NKTR) stock ahead of a pivotal Phase 3 rezpegaldesleukin trial has turned attention to how institutional investors are positioning around the company’s clinical pipeline and cash resources.
See our latest analysis for Nektar Therapeutics.
Despite Prosight’s purchase, Nektar’s share price has been under pressure in the near term, with the stock down 27.35% on a 30...